Modernizing the Accelerated Approval Pathway Act of 2022
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Modernizing the Accelerated Approval Pathway Act of 2022
This bill modifies provisions relating to the accelerated approval of drugs for serious or life-threatening diseases or conditions, including by requiring the Food and Drug Administration (FDA) to publish its reasons when it determines a postapproval study to be unnecessary. The bill also establishes a pilot program and an FDA council to support the development of drugs for rare diseases and ensure the appropriate use of the accelerated approval pathway, respectively.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S3077-3078)
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 4446: Modernizing the Accelerated Approval Pathway Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-S-4446/
"S. 4446: Modernizing the Accelerated Approval Pathway Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-4446/.
S. 4446, 117th Cong. (2026), https://openamerica.io/bill/117-S-4446/.
[S. 4446: Modernizing the Accelerated Approval Pathway Act of 2022](https://openamerica.io/bill/117-S-4446/)